<DOC>
	<DOCNO>NCT00668265</DOCNO>
	<brief_summary>This 16 week study efficacy quetiapine treat symptom generalize anxiety disorder ( GAD ) subject comorbid opiate dependence . The study conduct prospective , randomize , double-blind , placebo-controlled fashion . Study subject inpatient residential drug-treatment facility , enrol 1 year methadone-to-abstinence treatment plan . Subjects randomized receive either quetiapine placebo addition ongoing drug addiction treatment . Subjects follow 16 week variety psychometric assessment make . Hypothesis One : Compared placebo , Quetiapine demonstrate great reduction symptom anxiety subject GAD remit comorbid opiate abuse . Exploratory Hypotheses : Compared placebo , Quetiapine demonstrate great improvement psychosocial function compliance community norm subject enrol residential drug addiction treatment facility .</brief_summary>
	<brief_title>Anxiety Recovering Opiate Dependence</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent A diagnosis opiate dependence define Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) past two year . A diagnosis generalize anxiety disorder define Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) within past 6 month . Males female age 2155 year Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrollment Able understand comply requirement study Subjects must free illicit drug use past 3 month Subjects must receive methadone maintenance therapy least 3 month , least 2 week methadonefree Good health , assess medical history , physical examination laboratory test Pregnancy lactation Current diagnosis Axis I disorder GAD , substance dependence remission , nicotine dependence Patients , opinion investigator , pose imminent risk suicide danger self others Known intolerance lack response quetiapine fumarate , judge investigator Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir Use follow cytochrome P450 inducers 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomisation Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e.g . diabetes , angina pectoris , hypertension ) judge investigator Involvement planning conduct study Previous enrollment randomisation treatment present study . Participation another drug trial within 4 week prior enrollment study long accordance local requirement A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrollment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % . Admitted hospital treatment DM DM relate illness past 12 week . Not physician care DM Physician responsible patient 's DM care indicate patient 's DM control . Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomization . For thiazolidinediones ( glitazones ) period le 8 week . Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If diabetic patient meet one criterion , patient exclude even treat physician believe patient stable participate study . An absolute neutrophil count ( ANC ) 1.5 x 109 per liter Positive urine drug screen test drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>Opiate Dependence</keyword>
	<keyword>Methadone-Maintenance</keyword>
	<keyword>Drug Addiction Treatment</keyword>
</DOC>